Viridian Therapeutics is a clinical-stage biotechnology company focused on serious and rare diseases, with a lead franchise in thyroid eye disease (TED). Its pipeline centers on antibodies targeting the IGF-1 receptor, including an intravenous candidate and subcutaneous options intended for more convenient dosing. The company aims at autoimmune orbital disease and related indications rather than commercialized mass-market drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0.1 | — | -100.7 | — |
| Q3 2025 | 70.6 | — | -28.2 | — |
| Q4 2025 | 0.1 | — | -161.8 | — |
| Q1 2026 | 0.1 | — | -92 | — |
| Q2 2026 | 0.3 | 278.7% | -127.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Pony AI Inc. (PONY), Bel Fuse Inc. (BELFA), Fortrea Holdings Inc. (FTRE), ChipMOS TECHNOLOGIES INC. (IMOS), Perdoceo Education Corporation (PRDO), Bitdeer Technologies Group (BTDR)